Jos Jonkers

54.7k citations

237 papers · 21.4k indexed · 12 hit papers · h-index 74

Impact in

Oncology top 0.05%
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
Cancer Research top 0.2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 119
- Cancer Cells and Metastasis 44
- PARP inhibition in cancer therapy 40
- Cancer-related Molecular Pathways 28
Cancer Research 44
- Cancer Genomics and Diagnostics 31

Co-authors: Anton Berns Peter Bouwman Sven Rottenberg Hanneke van der Gulden Marc Vooijs Karin E. de Visser Piet Borst Kelly Kersten
Journals: Cancer Research (19 papers)The Journal of Pathology (11 papers)Journal of Mammary Gland Biology and Neoplasia (9 papers)Clinical Cancer Research (8 papers)Oncogene (8 papers)
Partner nations: Netherlands United Kingdom United States

In The Last Decade

Jos Jonkers

232 papers receiving 21.2k citations

Hit Papers

12 papers align trajectories log scale

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency 2021 · 229 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Molecular Cell
2021 Nature Reviews Clinical Oncology
2020 Annals of Oncology
2019 Nature
2019 Cancer Discovery
2015 Nature
2014 Cell
2014 Cancer Discovery
2012 Nature reviews. Cancer
2008 Proceedings of the National Academy of Sciences
2001 Nature Genetics
2000 Genes & Development

Peers

Countries citing papers authored by Jos Jonkers

Since Specialization

Citations

This map shows the geographic impact of Jos Jonkers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos Jonkers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos Jonkers more than expected).

Fields of papers citing papers by Jos Jonkers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jos Jonkers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos Jonkers. The network helps show where Jos Jonkers may publish in the future.

Co-authors

The 25 scholars most cited alongside Jos Jonkers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jos Jonkers Line = papers co-authored together Jos Jonkers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays Clinical Cancer Research ·Peter Bouwman, Ingrid van der Heijden, Hanneke van der Gulden, Roebi de Bruijn, Cordon E. Gross, Setareh Moghadasi, Lodewyk F.A. Wessels, (unknown), Maaike P.G. Vreeswijk, Jos Jonkers	2020	20
2	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms Cancer Research ·Koen Schipper, Anne Paulien Drenth, Eline van der Burg, LESTER J. PALMER, Sjoerd Klarenbeek, Micha Nethe, Jos Jonkers	2020	7
3	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors Cancer Research ·Marco Barazas, Alessia Gasparini, Yike Huang, Aslι Küçükosmanoğlu, Stefano Annunziato, Peter Bouwman, Wendy Sol, Ariena Kersbergen, Natalie Proost, Renske de Korte‐Grimmerink, Marieke van de Ven, Jos Jonkers, Gerben R. Borst, Sven Rottenberg	2018	36
4	Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547 Cancer Research ·Sjors M. Kas, Julian R. de Ruiter, Koen Schipper, Eva Schut, Lorenzo Bombardelli, Ellen Wientjens, Anne Paulien Drenth, Renske de Korte‐Grimmerink, Sunny Mahakena, Christopher Phillips, Paul Smith, Sjoerd Klarenbeek, Koen van de Wetering, Anton Berns, Lodewyk F.A. Wessels, Jos Jonkers	2018	30
5	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models Cancer Research ·Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, Rajesh Odedra, H. Shelton Brown, Janneke E. Jaspers, 博之野海, Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic, Sven Rottenberg, Jos Jonkers, Delia Marwah Azizah, Niall M.B. Martin, Keith W. Caldecott, Alan Lau, Mark J. O’Connor	2016	60
6	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors Clinical Cancer Research ·Lukas J.A.C. Hawinkels, Amaya García de Vinuesa, Madelon Paauwe, Marianna Kruithof‐de Julio, Eliza Wiercinska, Evangelia Pardali, Laura Mezzanotte, Stijn Keereweer, Tanya M. Braumuller, Hara Yuki, Jos Jonkers, Clemens W.G.M. Löwik, Marie‐José Goumans, Timo L.M. ten Hagen, Peter ten Dijke	2015	45
7	BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance Cancer Research ·Janneke E. Jaspers, Wendy Sol, Ariena Kersbergen, Andreas Schlicker, Charlotte Guyader, Guotai Xu, Lodewyk F.A. Wessels, Piet Borst, Jos Jonkers, Sven Rottenberg	2014	53
8	A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants Cancer Discovery ·Peter Bouwman, Hanneke van der Gulden, Ingrid van der Heijden, Rinske Drost, Christiaan Klijn, Pramudita R. Prasetyanti, Mark Pieterse, Ellen Wientjens, Jost Seibler, Frans B.L. Hogervorst, Jos Jonkers	2013	92
9	Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling Cancer Research ·Ron C.J. Schackmann, Sjoerd Klarenbeek, Eva J. Vlug, Suzan Stelloo, Miranda van Amersfoort, Milou Tenhagen, Tanya M. Braumuller, Jeroen F. Vermeulen, Petra van der Groep, Ton Peeters, Elsken van der Wall, P. J. van Diest, Jos Jonkers, Patrick W.B. Derksen	2013	48
10	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors Cancer Discovery ·Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Beyza Kavalci, James H. Doroshow, Aaron Cranston, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Shridar Ganesan, Piet Borst, Jos Jonkers, Sven Rottenberg	2012	388
11	A Preclinical Mouse Model of Invasive Lobular Breast Cancer Metastasis Cancer Research ·Chris W. Doornebal, Sjoerd Klarenbeek, Tanya M. Braumuller, Christiaan Klijn, Metamia Ciampricotti, Cheei‐Sing Hau, Markus W. Hollmann, Jos Jonkers, Karin E. de Visser	2012	55
12	Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol Cancer Prevention Research ·Serge A.L. Zander, Ariena Kersbergen, Wendy Sol, Maaike Gonggrijp, Koen van de Wetering, Jos Jonkers, Piet Borst, Sven Rottenberg	2012	13
13	Novel Candidate Cancer Genes Identified by a Large-Scale Cross-Species Comparative Oncogenomics Approach Cancer Research ·Richard Machin, Jaap Kool, Anthony G. Uren, Jeroen de Ridder, Lodewyk F.A. Wessels, Jos Jonkers, Graham R. Bignell, Adam P. Butler, Alistair G. Rust, Mario Brosch, Catherine H. Wilson, Louise van der Weyden, David A. Largaespada, Michael R. Stratton, P. Andy Futreal, Maarten van Lohuizen, Anton Berns, Lara S. Collier, Tim Hubbard, David J. Adams	2010	34
14	Insertional Mutagenesis in Mice Deficient for p15Ink4b, p16Ink4a, p21Cip1 , and p27Kip1 Reveals Cancer Gene Interactions and Correlations with Tumor Phenotypes Cancer Research ·Jaap Kool, Anthony G. Uren, Ejike Eze, Daoud Sie, Jeroen de Ridder, N. Bounasla, Miranda van Uitert, Konstantin Matentzoglu, Ефремов Олег Юрьевич, Paul Krimpenfort, Jules Gadiot, Colin E.J. Pritchard, Jack Lenz, Anders H. Lund, Jos Jonkers, Jane Rogers, David J. Adams, Lodewyk F.A. Wessels, Anton Berns, Maarten van Lohuizen	2010	25
15	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan Cancer Research ·Serge A.L. Zander, Ariena Kersbergen, Eline van der Burg, Chung Hsien Chou, Olaf van Tellingen, Alexander T. Galt Galt, Janneke E. Jaspers, Marina Pajic, Anders O.H. Nygren, Jos Jonkers, Piet Borst, Sven Rottenberg	2010	66
16	Fibroblast Growth Factor Receptor 1–Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival Cancer Research ·Wa Xian, Leontios Pappas, 慧祐山口, Laura M. Selfors, Patrick W.B. Derksen, Michiel de Bruin, Nathanael S. Gray, Jos Jonkers, Jeffrey M. Rosen, Joan S. Brugge	2009	61
17	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors Clinical Cancer Research ·Bastiaan Evers, Eva Schut, Eline van der Burg, Tanya M. Braumuller, David A. Egan, Henne Holstege, Pauline Edser, David J. Adams, Richard Wade‐Martins, Peter Bouwman, Jos Jonkers	2009	66
18	High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer Cancer Research ·Henne Holstege, Simon A. Joosse, Conny Th.M. van Oostrom, Petra M. Nederlof, Annemieke de Vries, Jos Jonkers	2009	124
19	CIP2A Is Associated with Human Breast Cancer Aggressivity Clinical Cancer Research ·Christophé Côme, Anni Laine, Maïa Chanrion, Henrik Edgren, Elina Mattila, Xiaoling Liu, Jos Jonkers, Johanna Ivaska, Jorma Isola, Jean-Marie Darbon, Olli Kallioniemi, Simon Thézenas, Jukka Westermarck	2009	185
20	Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage Cancer Research ·S. Wijnhoven, Ewoud N. Speksnijder, Xiaoling Liu, Edwin Zwart, Jabbar K. Abbass, Rudolf B. Beems, Esther M. Hoogervorst, Mirjam M. Schaap, Laura D. Attardi, Tyler Jacks, Harry van Steeg, Jos Jonkers, Annemieke de Vries	2007	39

About Jos Jonkers

Jos Jonkers is a scholar working on Oncology, Cancer Research, Molecular Biology, Genetics and Biotechnology, having authored 237 papers that have together received 21.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (61 papers), CRISPR and Genetic Engineering (48 papers), Cancer Cells and Metastasis (44 papers), PARP inhibition in cancer therapy (40 papers), BRCA gene mutations in cancer (33 papers), Cancer Genomics and Diagnostics (31 papers), Cancer-related Molecular Pathways (28 papers) and Epigenetics and DNA Methylation (21 papers). The work is most often cited by research in Oncology (10.3k citations), Cancer Research (4.1k citations), Molecular Biology (13.7k citations), Immunology (3.0k citations) and Genetics (3.2k citations). Jos Jonkers has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Anton Berns, Peter Bouwman, Sven Rottenberg, Hanneke van der Gulden, Marc Vooijs, Karin E. de Visser, Anton Berns, Piet Borst, Kelly Kersten and Patrick W.B. Derksen. Their work appears in journals such as Cancer Research, The Journal of Pathology, Journal of Mammary Gland Biology and Neoplasia, Clinical Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact